{"title":"一名海军飞行军官的功能性消化不良和三环类抗抑郁药的使用。","authors":"Robert Crutcher, Nathan Kolasinski","doi":"10.3357/AMHP.6404.2024","DOIUrl":null,"url":null,"abstract":"<p><p><b>BACKGROUND:</b> Functional dyspepsia is a disorder of gut-brain interaction that has the potential to impact aviation performance. Proton pump inhibitors are well-tolerated but are only effective in one half of cases. Second-line treatments, including tricyclic antidepressants, are associated with drowsiness and are not routinely approved for use in aviators. We present a case of a Naval Flight Officer with functional dyspepsia who was successfully treated with amitriptyline and returned to flying status.<b>CASE REPORT:</b> A 23-yr-old male Naval Flight Officer presented with postprandial fullness and epigastric pain. His symptoms were refractory to trials of acid suppression and lifestyle modification. An extensive evaluation by Gastroenterology, including upper endoscopy, did not reveal an organic cause of his symptoms and he was diagnosed with functional dyspepsia. The patient's symptoms resolved with a trial of amitriptyline. Neuropsychological testing demonstrated no medication effect on cognitive performance. A waiver to resume flying duties on amitriptyline was submitted to the Naval Aerospace Medical Institute and was approved.<b>DISCUSSION:</b> We present the second known waiver issued in U.S. Naval aviation history for the use of amitriptyline to treat a gastrointestinal disorder. Amitriptyline is not commonly waived due to the potential for unacceptable cognitive side-effects in the flight environment. However, neuropsychological testing to assess for a possible medication effect on performance can be used to inform an aeromedical disposition and, in this case, allowed for a return to flight status.<b>Crutcher R, Kolasinski N. <i>Functional dyspepsia and tricyclic antidepressant use in a naval flight officer</i>. Aerosp Med Hum Perform. 2024; 95(6):337-340.</b></p>","PeriodicalId":7463,"journal":{"name":"Aerospace medicine and human performance","volume":"95 6","pages":"337-340"},"PeriodicalIF":0.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Functional Dyspepsia and Tricyclic Antidepressant Use in a Naval Flight Officer.\",\"authors\":\"Robert Crutcher, Nathan Kolasinski\",\"doi\":\"10.3357/AMHP.6404.2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>BACKGROUND:</b> Functional dyspepsia is a disorder of gut-brain interaction that has the potential to impact aviation performance. Proton pump inhibitors are well-tolerated but are only effective in one half of cases. Second-line treatments, including tricyclic antidepressants, are associated with drowsiness and are not routinely approved for use in aviators. We present a case of a Naval Flight Officer with functional dyspepsia who was successfully treated with amitriptyline and returned to flying status.<b>CASE REPORT:</b> A 23-yr-old male Naval Flight Officer presented with postprandial fullness and epigastric pain. His symptoms were refractory to trials of acid suppression and lifestyle modification. An extensive evaluation by Gastroenterology, including upper endoscopy, did not reveal an organic cause of his symptoms and he was diagnosed with functional dyspepsia. The patient's symptoms resolved with a trial of amitriptyline. Neuropsychological testing demonstrated no medication effect on cognitive performance. A waiver to resume flying duties on amitriptyline was submitted to the Naval Aerospace Medical Institute and was approved.<b>DISCUSSION:</b> We present the second known waiver issued in U.S. Naval aviation history for the use of amitriptyline to treat a gastrointestinal disorder. Amitriptyline is not commonly waived due to the potential for unacceptable cognitive side-effects in the flight environment. However, neuropsychological testing to assess for a possible medication effect on performance can be used to inform an aeromedical disposition and, in this case, allowed for a return to flight status.<b>Crutcher R, Kolasinski N. <i>Functional dyspepsia and tricyclic antidepressant use in a naval flight officer</i>. Aerosp Med Hum Perform. 2024; 95(6):337-340.</b></p>\",\"PeriodicalId\":7463,\"journal\":{\"name\":\"Aerospace medicine and human performance\",\"volume\":\"95 6\",\"pages\":\"337-340\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aerospace medicine and human performance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3357/AMHP.6404.2024\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOPHYSICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aerospace medicine and human performance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3357/AMHP.6404.2024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0
摘要
背景:功能性消化不良是一种肠道与大脑相互作用的紊乱,有可能影响航空性能。质子泵抑制剂具有良好的耐受性,但仅对半数病例有效。包括三环类抗抑郁药在内的二线治疗与嗜睡有关,未被常规批准用于飞行员。病例报告:一名 23 岁的男性海军飞行军官出现餐后饱胀和上腹痛。他的症状对抑制胃酸和改变生活方式的试验无效。消化内科对其进行了广泛的评估,包括上消化道内窥镜检查,但并未发现导致其症状的器质性病因,因此诊断其为功能性消化不良。试用阿米替林后,患者的症状得到缓解。神经心理学测试表明,药物对认知能力没有影响。我们向海军航空航天医学研究所提交了使用阿米替林恢复飞行任务的豁免申请,并获得了批准。讨论:我们介绍了美国海军航空史上第二例使用阿米替林治疗胃肠道疾病的豁免申请。由于阿米替林在飞行环境中可能会产生令人无法接受的认知副作用,因此并不常见。然而,通过神经心理学测试来评估药物对表现可能产生的影响,可以为航空医学处置提供依据,在本病例中,可以恢复飞行状态。Aerosp Med Hum Perform.2024; 95(6):337-340.
Functional Dyspepsia and Tricyclic Antidepressant Use in a Naval Flight Officer.
BACKGROUND: Functional dyspepsia is a disorder of gut-brain interaction that has the potential to impact aviation performance. Proton pump inhibitors are well-tolerated but are only effective in one half of cases. Second-line treatments, including tricyclic antidepressants, are associated with drowsiness and are not routinely approved for use in aviators. We present a case of a Naval Flight Officer with functional dyspepsia who was successfully treated with amitriptyline and returned to flying status.CASE REPORT: A 23-yr-old male Naval Flight Officer presented with postprandial fullness and epigastric pain. His symptoms were refractory to trials of acid suppression and lifestyle modification. An extensive evaluation by Gastroenterology, including upper endoscopy, did not reveal an organic cause of his symptoms and he was diagnosed with functional dyspepsia. The patient's symptoms resolved with a trial of amitriptyline. Neuropsychological testing demonstrated no medication effect on cognitive performance. A waiver to resume flying duties on amitriptyline was submitted to the Naval Aerospace Medical Institute and was approved.DISCUSSION: We present the second known waiver issued in U.S. Naval aviation history for the use of amitriptyline to treat a gastrointestinal disorder. Amitriptyline is not commonly waived due to the potential for unacceptable cognitive side-effects in the flight environment. However, neuropsychological testing to assess for a possible medication effect on performance can be used to inform an aeromedical disposition and, in this case, allowed for a return to flight status.Crutcher R, Kolasinski N. Functional dyspepsia and tricyclic antidepressant use in a naval flight officer. Aerosp Med Hum Perform. 2024; 95(6):337-340.
期刊介绍:
The peer-reviewed monthly journal, Aerospace Medicine and Human Performance (AMHP), formerly Aviation, Space, and Environmental Medicine, provides contact with physicians, life scientists, bioengineers, and medical specialists working in both basic medical research and in its clinical applications. It is the most used and cited journal in its field. It is distributed to more than 80 nations.